FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214821242> ?p ?o ?g. }

• W4214821242 endingPage "287" @default.
• W4214821242 startingPage "287" @default.
• W4214821242 abstract "Schema therapy (ST), delivered either in an individual or group format, has been compared with other active treatments for borderline personality disorder (BPD). To our knowledge, the 2 formats have not been compared with treatment as usual (TAU) or with each other. Such comparisons help determine best treatment practices.To evaluate whether ST is more effectively delivered in a predominantly group or combined individual and group format and whether ST is more effective than optimal TAU for BPD.In this multicenter, 3-arm randomized clinical trial conducted at 15 sites in 5 countries (Australia, Germany, Greece, the Netherlands, and the UK), outpatients aged 18 to 65 years who had BPD were recruited between June 29, 2010, and May 18, 2016, to receive either predominantly group ST (PGST), combined individual and group ST (IGST), or optimal TAU. Data were analyzed from June 4, 2019, to December 29, 2021.At each site, cohorts of 16 to 18 participants were randomized 1:1 to PGST vs TAU or IGST vs TAU. Both ST formats were delivered over 2 years, with 2 sessions per week in year 1 and the frequency gradually decreasing during year 2. Assessments were collected by blinded assessors.The primary outcome was the change in BPD severity over time, assessed with the Borderline Personality Disorder Severity Index (BPDSI) total score. Treatment retention was analyzed as a secondary outcome using generalized linear mixed model survival analysis.Of 495 participants (mean [SD] age, 33.6 [9.4] years; 426 [86.2%] female), 246 (49.7%) received TAU, 125 (25.2%) received PGST, and 124 (25.0%) received IGST (1 of whom later withdrew consent). PGST and IGST combined were superior to TAU with regard to reduced BPD severity (Cohen d, 0.73; 95% CI, 0.29-1.18; P < .001). For this outcome, IGST was superior to TAU (Cohen d, 1.14; 95% CI, 0.57-1.71; P < .001) and PGST (Cohen d, 0.84; 95% CI, 0.09-1.59; P = .03), whereas PGST did not differ significantly from TAU (Cohen d, 0.30; 95% CI, -0.29 to 0.89; P = .32). Treatment retention was greater in the IGST arm than in the PGST (1 year: 0.82 vs 0.72; 2 years: 0.74 vs. 0.62) and TAU (1 year: 0.82 vs 0.73; 2 years: 0.74 vs 0.64) arms, and there was no significant difference between the TAU and PGST arms (1 year: 0.73 vs 0.72; 2 years: 0.64 vs 0.62).In this randomized clinical trial, IGST was more effective and had greater treatment retention compared with TAU and PGST. These findings suggest that IGST is the preferred ST format, with high retention and continuation of improvement in BPD severity after the completion of treatment.trialregister.nl Identifier: NTR2392." @default.
• W4214821242 created "2022-03-05" @default.
• W4214821242 creator A5003735602 @default.
• W4214821242 creator A5003763447 @default.
• W4214821242 creator A5020180851 @default.
• W4214821242 creator A5028958868 @default.
• W4214821242 creator A5033514995 @default.
• W4214821242 creator A5045996745 @default.
• W4214821242 creator A5058365433 @default.
• W4214821242 creator A5063492720 @default.
• W4214821242 creator A5064470371 @default.
• W4214821242 creator A5064908894 @default.
• W4214821242 creator A5067049301 @default.
• W4214821242 creator A5070400321 @default.
• W4214821242 creator A5071755987 @default.
• W4214821242 creator A5077983383 @default.
• W4214821242 date "2022-04-01" @default.
• W4214821242 modified "2023-10-18" @default.
• W4214821242 title "Effectiveness of Predominantly Group Schema Therapy and Combined Individual and Group Schema Therapy for Borderline Personality Disorder" @default.
• W4214821242 cites W2019444600 @default.
• W4214821242 cites W2040979679 @default.
• W4214821242 cites W2082786279 @default.
• W4214821242 cites W2096230543 @default.
• W4214821242 cites W2096356290 @default.
• W4214821242 cites W2107959833 @default.
• W4214821242 cites W2116997906 @default.
• W4214821242 cites W2136456709 @default.
• W4214821242 cites W2136936994 @default.
• W4214821242 cites W2149328982 @default.
• W4214821242 cites W2152290504 @default.
• W4214821242 cites W2156247218 @default.
• W4214821242 cites W2429180991 @default.
• W4214821242 cites W2787671994 @default.
• W4214821242 cites W2885938281 @default.
• W4214821242 cites W2901053109 @default.
• W4214821242 cites W3000509725 @default.
• W4214821242 cites W3124593434 @default.
• W4214821242 cites W3184595783 @default.
• W4214821242 cites W4230612000 @default.
• W4214821242 cites W4249465587 @default.
• W4214821242 doi "https://doi.org/10.1001/jamapsychiatry.2022.0010" @default.
• W4214821242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35234828" @default.
• W4214821242 hasPublicationYear "2022" @default.
• W4214821242 type Work @default.
• W4214821242 citedByCount "26" @default.
• W4214821242 countsByYear W42148212422022 @default.
• W4214821242 countsByYear W42148212422023 @default.
• W4214821242 crossrefType "journal-article" @default.
• W4214821242 hasAuthorship W4214821242A5003735602 @default.
• W4214821242 hasAuthorship W4214821242A5003763447 @default.
• W4214821242 hasAuthorship W4214821242A5020180851 @default.
• W4214821242 hasAuthorship W4214821242A5028958868 @default.
• W4214821242 hasAuthorship W4214821242A5033514995 @default.
• W4214821242 hasAuthorship W4214821242A5045996745 @default.
• W4214821242 hasAuthorship W4214821242A5058365433 @default.
• W4214821242 hasAuthorship W4214821242A5063492720 @default.
• W4214821242 hasAuthorship W4214821242A5064470371 @default.
• W4214821242 hasAuthorship W4214821242A5064908894 @default.
• W4214821242 hasAuthorship W4214821242A5067049301 @default.
• W4214821242 hasAuthorship W4214821242A5070400321 @default.
• W4214821242 hasAuthorship W4214821242A5071755987 @default.
• W4214821242 hasAuthorship W4214821242A5077983383 @default.
• W4214821242 hasBestOaLocation W42148212421 @default.
• W4214821242 hasConcept C118552586 @default.
• W4214821242 hasConcept C119857082 @default.
• W4214821242 hasConcept C126322002 @default.
• W4214821242 hasConcept C15744967 @default.
• W4214821242 hasConcept C168563851 @default.
• W4214821242 hasConcept C1862650 @default.
• W4214821242 hasConcept C187212893 @default.
• W4214821242 hasConcept C2780600973 @default.
• W4214821242 hasConcept C41008148 @default.
• W4214821242 hasConcept C52146309 @default.
• W4214821242 hasConcept C70410870 @default.
• W4214821242 hasConcept C71924100 @default.
• W4214821242 hasConceptScore W4214821242C118552586 @default.
• W4214821242 hasConceptScore W4214821242C119857082 @default.
• W4214821242 hasConceptScore W4214821242C126322002 @default.
• W4214821242 hasConceptScore W4214821242C15744967 @default.
• W4214821242 hasConceptScore W4214821242C168563851 @default.
• W4214821242 hasConceptScore W4214821242C1862650 @default.
• W4214821242 hasConceptScore W4214821242C187212893 @default.
• W4214821242 hasConceptScore W4214821242C2780600973 @default.
• W4214821242 hasConceptScore W4214821242C41008148 @default.
• W4214821242 hasConceptScore W4214821242C52146309 @default.
• W4214821242 hasConceptScore W4214821242C70410870 @default.
• W4214821242 hasConceptScore W4214821242C71924100 @default.
• W4214821242 hasIssue "4" @default.
• W4214821242 hasLocation W42148212421 @default.
• W4214821242 hasLocation W42148212422 @default.
• W4214821242 hasLocation W42148212423 @default.
• W4214821242 hasLocation W42148212424 @default.
• W4214821242 hasOpenAccess W4214821242 @default.
• W4214821242 hasPrimaryLocation W42148212421 @default.
• W4214821242 hasRelatedWork W1998939506 @default.
• W4214821242 hasRelatedWork W2083871338 @default.
• W4214821242 hasRelatedWork W2748952813 @default.
• W4214821242 hasRelatedWork W2899084033 @default.

• next